Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 4Lymphoid 4Breast 4Other hematologic neoplasm 3Other solid neoplasm 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1Myeloid 1

Conditions

Melanoma 2

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Base Sequence × Dermatologic × Clear all
NCT01543113 2023-05-24

KitMel

Rennes University Hospital

Phase NA Completed
288 enrolled
Dermatologic

Melanoma

NCT04285749 2020-07-27

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡